Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moExternal Resources
ERYTHROMYCIN by Bausch + Lomb is clinical pharmacology erythromycin diffuses readily into most body fluids. Approved for penicillin-allergic patients, the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below, the severity of the infection requires immediate high serum levels of erythromycin. First approved in 1994.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin crosses the placental…
Worked on ERYTHROMYCIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood
Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo